Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Pediatrics UCSF Medical Center

Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.

  • Read more about Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.

ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALL.

  • Read more about ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALL.

Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC.

  • Read more about Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC.

Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1.

  • Read more about Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1.

Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.

  • Read more about Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.

Liberalizing Hospital Proximity Requirements for Children/Young Adults with Low Burden B-ALL Receiving Tisagenlecleucel.

  • Read more about Liberalizing Hospital Proximity Requirements for Children/Young Adults with Low Burden B-ALL Receiving Tisagenlecleucel.

Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children's Oncology Group report.

  • Read more about Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children's Oncology Group report.

Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR Analysis.

  • Read more about Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR Analysis.

Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecel.

  • Read more about Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecel.

Real World Outcomes for Young Adult Patients Receiving CD19 CAR T-cell Therapy.

  • Read more about Real World Outcomes for Young Adult Patients Receiving CD19 CAR T-cell Therapy.

Pagination

  • Page 1
  • Next page ››
Subscribe to Blood advances

Pediatrics Home

MAKE A GIFT

© 2022 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Pediatrics                                                                                              Accessibility  Privacy Policy  Terms of Use  A-Z Website List